{"id":"NCT01976312","sponsor":"Novartis Pharmaceuticals","briefTitle":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)","officialTitle":"A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-12","primaryCompletion":"2016-03-14","completion":"2016-03-14","firstPosted":"2013-11-05","resultsPosted":"2017-04-24","lastUpdate":"2017-05-30"},"enrollment":252,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Central Retinal Vein Occlusion"],"interventions":[{"type":"OTHER","name":"Sham injection","otherNames":[]},{"type":"DRUG","name":"Ranibizumab 0.5 mg","otherNames":["Lucentis"]}],"arms":[{"label":"Ranibizumab 0.5 mg","type":"EXPERIMENTAL"},{"label":"Sham injection","type":"SHAM_COMPARATOR"}],"summary":"Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO","primaryOutcome":{"measure":"Average Change in Visual Acuity (Letters) From Baseline to Month 1 Through Month 3","timeFrame":"Baseline, 3 Months","effectByArm":[{"arm":"Ranibizumab 0.5 mg","deltaMin":11.3,"sd":10.77},{"arm":"Sham Injection","deltaMin":-2.7,"sd":13.92}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":7},"locations":{"siteCount":34,"countries":["China","Hong Kong","India","Indonesia","Philippines","Taiwan","Vietnam"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":190},"commonTop":["Nasopharyngitis","Conjunctival haemorrhage","Upper respiratory tract infection","Hypertension","Visual acuity reduced"]}}